2024
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
Wang M, Gwee Y, Lin Z, Yong W, Sundar R, Tan H, Choo J, Tan K, Lieske B, Cheong W, Tan T, Tey J, Chee C, Chan G. Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center. Journal Of Clinical Oncology 2024, 42: 39-39. DOI: 10.1200/jco.2024.42.3_suppl.39.Peer-Reviewed Original ResearchLocally advanced rectal cancerTotal neoadjuvant therapyPathological complete responseDisease-free survivalClinical complete responseCircumferential resection marginCycles of XELOXTumor regression gradeCycles of mFOLFOX6Systemic chemotherapyComplete responseR0 resectionRectal cancerRate of clinical complete responseCycles of systemic chemotherapyPathologic complete response rateThreatened circumferential resection marginCircumferential resection margin involvementDisease-free survival ratesWatch-and-wait approachLimitations of retrospective studiesLong-course CRTMedian tumor distanceAdequate organ functionLong-course chemoradiation
2016
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer
Wong A, Sundar R, Wang T, Ng T, Zhang B, Tan S, Soh T, Pang A, Tan C, Ow S, Wang L, Mogro J, Ho J, Jeyasekharan A, Huang Y, Thng C, Chan C, Hartman M, Iau P, Buhari S, Goh B, Lee S. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget 2016, 7: 64089-64099. PMID: 27577069, PMCID: PMC5325427, DOI: 10.18632/oncotarget.11596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnthracyclinesAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsContrast MediaCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Administration ScheduleFemaleHumansImmunohistochemistryIndolesMagnetic Resonance ImagingMiddle AgedNeoadjuvant TherapyPreoperative PeriodPyrrolesSunitinibTreatment OutcomeConceptsPathological complete responseVascular normalization indexChemotherapy dose delaysLow-doseDose delaysDCE-MRIPhase IbDecreased lymphatic vessel densityIntra-tumoral drug deliveryPathologic complete response rateRecommended phase II dosePhase II doseDose of sunitinibTreatment of breast cancerDCE-MRI parametersPre-operative treatmentAnthracycline-based chemotherapyOpen-label studyRandomized to chemotherapyTumor vessel normalizationLymphatic vessel densityEnhance chemotherapy efficacyBreast cancer patientsFunctional imaging biomarkersPharmacodynamic evidence